Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Optimizing the Synergy Between Behavioural Activation Therapy and Intravenous Ketamine for Treatment-Resistant Depression

NCT07801703 is registered in ClinicalTrials.gov with The Royal's Institute of Mental Health Research as lead sponsor.

NCT NCT07801703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07801703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Optimizing the Synergy Between Behavioural Activation Therapy and Intravenous Ketamine for Treatment-Resistant Depression
Lead sponsor
The Royal's Institute of Mental Health Research
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2029
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd), treatment resistant depression